NICE Backs Pfizer’s Xalkori In Lung Cancer After Firm Cuts Price (Again)

Pfizer’s oral therapy Xalkori (criotinib) for ALK-positive non-small cell lung cancer wins backing by the UK HTA after drug maker offers bigger discount than previously made and more supporting data.